Mary Katherine (Mary Kay) Ladone has served on our Board since 2022 and is currently the Chairperson of our Compensation Committee and a member of the Audit Committee. Ms. Ladone served as Senior Vice President, Corporate Development, Strategy and Investor Relations, of Hill-Rom Holdings, Inc. (Hill-Rom), a medical technology company, from December 2018 until January 2022 and previously served as Vice President, Investor Relations, of Hill-Rom from July 2016 to December 2018. Prior to Hill-Rom, from July 2015 until July 2016, Ms. Ladone served as Senior Vice President, Investor Relations Officer of Baxalta Inc., a biopharmaceutical company. Prior to Baxalta, Ms. Ladone served in a variety of senior finance, business development, operational, and investor relations roles for Baxter International, Inc. from 1998 until July 2015. Ms. Ladone currently serves on the board of directors of Bioventus, Inc. (Nasdaq: BVS), a medical device company, as a member of its audit committee and compensation committee and Kestra Medical Technologies (Nasdaq: KMTS), a medical device company, as the chair of its audit committee and a member of the nominating and governance committee. She also joined the board of directors of Novanta Inc. (Nasdaq: NOVT), a global supplier of core technology solutions, in July 2024. Ms. Ladone has been a member of the board of directors of Endeavor Health, a comprehensive community-based health system, since 2009 and serves as vice chairman and the chair of the investment committee. Ms. Ladone holds a Bachelor's in Business Administration from the University of Notre Dame. Qualifications: The Board believes that Ms. Ladone is qualified to serve as a director based on her extensive experience in corporate strategy, capital markets, and public company governance within the healthcare sector. Ms. Ladone has held multiple senior executive roles at global medical technology companies where she supported significant strategic transformation initiatives. She brings substantial experience in mergers and acquisitions, investor relations, financial oversight, and risk management, as well as oversight of technology and digital health investments. Ms. Ladone also offers relevant governance expertise through her audit committee and compensation committee service at other public medical technology companies.